PAM Theragnostics

Executive Summary

PAM Theragnostics is a Berlin-based biotech startup founded in 2020, pioneering a novel approach to Alzheimer's disease by targeting vascular contributions to neurodegeneration. Unlike traditional amyloid-focused strategies, the company leverages the PAM enzyme to activate protective vascular peptide hormones, aiming to restore cerebral blood flow and blood-brain barrier integrity. This dual diagnostic and therapeutic platform positions PAM Theragnostics at the forefront of early detection and intervention, addressing a critical unmet need in Alzheimer's care. The company's diagnostic tools are designed to identify vascular dysfunction before significant cognitive decline, while its therapeutic strategy seeks to halt or reverse disease progression by enhancing the brain's intrinsic protective mechanisms. Currently in the pre-clinical stage, PAM Theragnostics is advancing its technology through in vitro and in vivo studies, with a focus on validating the PAM enzyme's role in Alzheimer's pathology. The startup operates in Germany's vibrant biotech ecosystem and has not yet disclosed funding rounds or partnerships. If successful, its vascular-targeted approach could complement existing therapies, offering a new avenue for patients with mixed dementia pathologies. The next 12-18 months are critical for generating proof-of-concept data to attract investors and potential pharmaceutical partners, as the company moves toward preclinical milestones.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data publication60% success
• TBDSeries A financing round40% success
• TBDAcademic or industry partnership for development30% success